4//SEC Filing
BP Directors, LP 4
Accession 0001813316-20-000002
CIK 0001763950other
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 6:21 PM ET
Size
37.4 KB
Accession
0001813316-20-000002
Insider Transaction Report
Form 4
Kreis Leslie W.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-06-15−80,454→ 0 total(indirect: By Bios Fund II, LP)→ Common Stock (139,989 underlying) - Conversion
Common Stock
2020-06-15+294,557→ 294,557 total(indirect: By Bios Fund I QP, LP) - Conversion
Common Stock
2020-06-15+503,606→ 503,606 total(indirect: By Bios Fund I, LP) - Conversion
Common Stock
2020-06-15+457,282→ 668,738 total(indirect: By Bios Fund II QP, LP) - Conversion
Common Stock
2020-06-15+61,214→ 89,522 total(indirect: By Bios Fund II NT, LP) - Award
Stock Options
2020-06-15+9,135→ 9,135 totalExercise: $15.00Exp: 2030-06-14→ Common Stock (9,135 underlying) - Conversion
Common Stock
2020-06-15+139,989→ 204,723 total(indirect: By Bios Fund II, LP) - Conversion
Series A Preferred Stock
2020-06-15−289,429→ 0 total(indirect: By Bios Fund I, LP)→ Common Stock (503,606 underlying) - Conversion
Series A Preferred Stock
2020-06-15−169,286→ 0 total(indirect: By Bios Fund I QP, LP)→ Common Stock (294,557 underlying) - Conversion
Series A Preferred Stock
2020-06-15−262,806→ 0 total(indirect: By Bios Fund II QP, LP)→ Common Stock (457,282 underlying) - Conversion
Series A Preferred Stock
2020-06-15−35,181→ 0 total(indirect: By Bios Fund II NT, LP)→ Common Stock (61,214 underlying)
Footnotes (11)
- [F1]In connection with the Issuer's initial public offering ("IPO"), the Issuer effected a 1.74-for-1 stock split on its outstanding common stock, which became effective immediately prior to the closing of the Issuer's IPO ("Stock Split"). The share amounts reflect the Stock Split.
- [F10]Pursuant to a pre-exiting agreement, Mr. Kreis is deemed to hold the reported option for the benefit of Bios Director. Bios Directors may be deemed the indirect beneficial owner of the option, and Bios Equity I, Cavu Management, Cavu Advisors and Mr. Kreis may each be deemed the indirect beneficial owner of the option through its or his indirect interest in Bios Directors.
- [F11]For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- [F2]In connection with the Issuer's IPO, the 289,429 shares of the Issuer's Series A Preferred Stock held by Bios Fund I, LP ("Bios Fund I"), which had no expiration date, were automatically converted for no additional consideration into 503,606 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F3]In connection with the Issuer's IPO, the 169,286 shares of the Issuer's Series A Preferred Stock held by Bios Fund I QP, LP ("Bios Fund I QP"), which had no expiration date, were automatically converted for no additional consideration into 294,557 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F4]In connection with the Issuer's IPO, the 80,454 shares of the Issuer's Series A Preferred Stock held by Bios Fund II, LP ("Bios Fund II"), which had no expiration date, were automatically converted for no additional consideration into 139,989 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F5]In connection with the Issuer's IPO, the 262,806 shares of the Issuer's Series A Preferred Stock held by Bios Fund II QP, LP ("Bios Fund II QP"), which had no expiration date, were automatically converted for no additional consideration into 457,282 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F6]In connection with the Issuer's IPO, the 35,181 shares of the Issuer's Series A Preferred Stock held by Bios Fund II NT, LP ("Bios Fund II NT"), which had no expiration date, were automatically converted for no additional consideration into 61,214 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F7]Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management.
- [F8]Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- [F9]Mr. Kreis was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001813311
Filing Metadata
- Form type
- 4
- Filed
- Jun 15, 8:00 PM ET
- Accepted
- Jun 16, 6:21 PM ET
- Size
- 37.4 KB